159 related articles for article (PubMed ID: 31029831)
1. Injectable biomaterials for delivery of interleukin-1 receptor antagonist: Toward improving its therapeutic effect.
Clements AEB; Murphy WL
Acta Biomater; 2019 Jul; 93():123-134. PubMed ID: 31029831
[TBL] [Abstract][Full Text] [Related]
2. Microparticles Locally Deliver Active Interleukin-1 Receptor Antagonist In Vivo.
Clements AEB; Groves ER; Chamberlain CS; Vanderby R; Murphy WL
Adv Healthc Mater; 2018 Aug; 7(16):e1800263. PubMed ID: 29974661
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of a fusion protein between thermally responsive elastin-like polypeptide and interleukin-1 receptor antagonist: sustained release of a local antiinflammatory therapeutic.
Shamji MF; Betre H; Kraus VB; Chen J; Chilkoti A; Pichika R; Masuda K; Setton LA
Arthritis Rheum; 2007 Nov; 56(11):3650-61. PubMed ID: 17968946
[TBL] [Abstract][Full Text] [Related]
4. PASylation of IL-1 receptor antagonist (IL-1Ra) retains IL-1 blockade and extends its duration in mouse urate crystal-induced peritonitis.
Powers NE; Swartzwelter B; Marchetti C; de Graaf DM; Lerchner A; Schlapschy M; Datar R; Binder U; Edwards CK; Skerra A; Dinarello CA
J Biol Chem; 2020 Jan; 295(3):868-882. PubMed ID: 31819009
[TBL] [Abstract][Full Text] [Related]
5. In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii.
Ricci S; Macchia G; Ruggiero P; Maggi T; Bossù P; Xu L; Medaglini D; Tagliabue A; Hammarström L; Pozzi G; Boraschi D
BMC Biotechnol; 2003 Sep; 3():15. PubMed ID: 13129437
[TBL] [Abstract][Full Text] [Related]
6. Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases.
Lavi G; Voronov E; Dinarello CA; Apte RN; Cohen S
J Control Release; 2007 Nov; 123(2):123-30. PubMed ID: 17900737
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis.
Volarevic V; Al-Qahtani A; Arsenijevic N; Pajovic S; Lukic ML
Autoimmunity; 2010 Jun; 43(4):255-63. PubMed ID: 19845478
[TBL] [Abstract][Full Text] [Related]
8. IL-1Ra and its delivery strategies: inserting the association in perspective.
Akash MS; Rehman K; Chen S
Pharm Res; 2013 Nov; 30(11):2951-66. PubMed ID: 23794040
[TBL] [Abstract][Full Text] [Related]
9. Selective delivery of interleukine-1 receptor antagonist to inflamed joint by albumin fusion.
Liu M; Huang Y; Hu L; Liu G; Hu X; Liu D; Yang X
BMC Biotechnol; 2012 Sep; 12():68. PubMed ID: 23006786
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of interleukin 1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody.
McIntyre KW; Stepan GJ; Kolinsky KD; Benjamin WR; Plocinski JM; Kaffka KL; Campen CA; Chizzonite RA; Kilian PL
J Exp Med; 1991 Apr; 173(4):931-9. PubMed ID: 1826128
[TBL] [Abstract][Full Text] [Related]
11. The interleukin-1 receptor antagonist and its delivery by gene transfer.
Evans CH; Robbins PD
Receptor; 1994; 4(1):9-15. PubMed ID: 8038709
[TBL] [Abstract][Full Text] [Related]
12. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde?
Perrier S; Darakhshan F; Hajduch E
FEBS Lett; 2006 Nov; 580(27):6289-94. PubMed ID: 17097645
[TBL] [Abstract][Full Text] [Related]
13. Mucosal delivery of anti-inflammatory IL-1Ra by sporulating recombinant bacteria.
Porzio S; Bossù P; Ruggiero P; Boraschi D; Tagliabue A
BMC Biotechnol; 2004 Oct; 4():27. PubMed ID: 15516267
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of interleukin-1 (alpha and beta), interleukin-2 secretion and surface expression of interleukin-2 receptor (IL-2R) by a novel cytokine interleukin-1 receptor antagonist (IL-1ra).
Conti P; Panara MR; Porrini AM; Gambi D; Barbacane RC; Reale M; Bongrazio M; Dempsey RA
Scand J Immunol; 1992 Jul; 36(1):27-33. PubMed ID: 1535451
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-1 receptor antagonist.
Lennard AC
Crit Rev Immunol; 1995; 15(1):77-105. PubMed ID: 8519423
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1 receptor antagonist: a new therapy for type 2 diabetes mellitus.
Akash MS; Shen Q; Rehman K; Chen S
J Pharm Sci; 2012 May; 101(5):1647-58. PubMed ID: 22271340
[TBL] [Abstract][Full Text] [Related]
17. Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials.
Akash MS; Rehman K; Li N; Gao JQ; Sun H; Chen S
Pharm Res; 2012 Dec; 29(12):3475-85. PubMed ID: 22907416
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice.
Sugihara T; Okiyama N; Watanabe N; Miyasaka N; Kohsaka H
Arthritis Rheum; 2012 Aug; 64(8):2655-62. PubMed ID: 22392010
[TBL] [Abstract][Full Text] [Related]
19. Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist.
Smeets RL; Joosten LA; Arntz OJ; Bennink MB; Takahashi N; Carlsen H; Martin MU; van den Berg WB; van de Loo FA
Arthritis Rheum; 2005 Jul; 52(7):2202-11. PubMed ID: 15986350
[TBL] [Abstract][Full Text] [Related]
20. SCIL-STROKE (Subcutaneous Interleukin-1 Receptor Antagonist in Ischemic Stroke): A Randomized Controlled Phase 2 Trial.
Smith CJ; Hulme S; Vail A; Heal C; Parry-Jones AR; Scarth S; Hopkins K; Hoadley M; Allan SM; Rothwell NJ; Hopkins SJ; Tyrrell PJ
Stroke; 2018 May; 49(5):1210-1216. PubMed ID: 29567761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
